MSB 13.4% $1.31 mesoblast limited

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-546

  1. 1,900 Posts.
    lightbulb Created with Sketch. 490
    Most here agree that the answer to that question is going to be a big, fat "it depends", or "depended" if talking in the past tense. Those paying attention to the communications, as vague as they can be, knew what near-term announcements could entail, positive or negative.

    In my opinion... Moving forward a BLA resubmission can put this over a dollar and if it's a quick approval that catches shorts of guard, say a few weeks into a class 1 resubmission that already had a shorter timeline, this could easily go into the multiple dollars.
    In my opinion... A submission for Heart Failure AA would have the same effect, but a much larger response on approval considering the size of the market.
    So that 86c in 3 weeks - yes a lot of people here recognised the potential.

    Could it happen again? It depends.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.31
Change
0.155(13.4%)
Mkt cap ! $1.341B
Open High Low Value Volume
$1.15 $1.33 $1.15 $14.11M 11.45M

Buyers (Bids)

No. Vol. Price($)
5 19864 $1.31
 

Sellers (Offers)

Price($) Vol. No.
$1.32 24178 11
View Market Depth
Last trade - 14.59pm 23/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.